Tarsa Therapeutics

About:

Tarsa Therapeutics develops an oral formulation of calcitonin for the treatment and prevention of postmenopausal osteoporosis.

Website: http://www.tarsatherapeutics.com

Top Investors: Foresite Capital, Novo Holdings, Marker, MVM Life Science Partners, Oxford Finance LLC

Description:

Tarsa Therapeutics is developing an oral formulation of calcitonin, a peptide hormone for the treatment of osteoporosis that slows the rate of bone destruction.

Total Funding Amount:

$124M

Estimated Revenue Range:

$1M to $10M

Headquarters Location:

Philadelphia, Pennsylvania, United States

Founded Date:

2009-01-01

Founders:

David Brand, James Gilligan

Number of Employees:

11-50

Last Funding Date:

2016-07-15

IPO Status:

Private

Industries: